Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
Medullary Thyroid Cancer
DRUG: Anlotinib Hydrochloride Capsule
Overall Response Rate (ORR), The proportion of subjects who achieves a best overall response of complete response (CR) or partial response (PR)., Baseline up to 3 years.|Progression-free Survival (PFS), From the first dose of investigational drug to the date of disease progression or death, whichever occurs first., Baseline up to 3 years.
Disease-control Rate (DCR), The proportion of subjects response of CR, PR, or stable disease (SD) (subjects achieving SD will be included in the DCR if they maintain SD for â‰¥4 weeks)., Baseline up to 3 years.|Duration of Response (DOR), From the date that CR or PR are first occurred to the date of disease progression or death, whichever occurs first., Baseline up to 3 years.|Overall Survival (OS), From randomization to the time of death from any cause., Baseline up to death event, up to 3 years.|Adverse event rate, The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)., Baseline up to 3 years.
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.